Pure Global AI
NCT06336954Not yet recruiting

Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

Exploratory Study of Adibelimab Combined With Famitinib and Chemotherapy for the Treatment of Patients With Driver Gene-Negative Locally Advanced or Metastatic NSCLC Progressing After PD-1 Monoclonal Antibody Combined With Chemotherapy
Second Affiliated Hospital of Xi'an Jiaotong UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Adibelimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Timeline & enrollment
Phase
Phase 2
Start date
Mar 30, 2024
End date
Dec 31, 2026
Enrollment
40 participants
Primary outcome

Progression-free survival time (PFS)

Summary

This prospective, single-arm trial explores the efficacy of Adibelimab monoclonal antibody
 combined with Famitinib and chemotherapy in treating locally advanced or metastatic NSCLC
 patients with negative driver genes who have progressed after PD-1 monoclonal antibody and
 chemotherapy treatment. The study focuses on assessing progression-free survival (PFS) in 40
 participants. Key objectives include evaluating PFS and understanding the progression
 patterns post-first-line immunotherapy, with an interest in whether switching from PD-1 to
 PD-L1 inhibitors can overcome immune resistance.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06336954
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06336954 through Pure Global AI's free database. This Phase 2 trial is sponsored by Second Affiliated Hospital of Xi'an Jiaotong University and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.